INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

    NEXT STORY
    Lux Research Releases In-Depth Benchmark Study on Sugar Replacement Technologies
    PREV STORY
    Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

    author_avatar
    NASDAQ Market News

    EyePoint Pharmaceuticals’ YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    author_avatar
    NASDAQ Market News

    Prefilled Syringes Market to Reach USD 10.57 Billion by 2026; Introduction of BD’s Disposable Autoinjector to Aid Expansion, states Fortune Business Insights™

    author_avatar
    NASDAQ Market News